BioWorld

Nov. 20, 2006

FDA Approves Herceptin In Adjuvant Breast Cancer

The FDA granted a broader label to Herceptin (trastuzumab), paving the way for Genentech Inc. to promote its most visible targeted oncology product as a front-line treatment for breast cancer.(BioWorld Today) Read More

British Consolidation: Innovata Bought By Vectura For £131.9M

Filling The Pipeline: 'Early Stage' Firm Varies In Eyes Of Beholder

Advanced Magnetics Rises On Positive Phase III Data

Medicure Starts Pivotal Trial Of MC-1 In Bypass Patients

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...